

Theodore M. Collins

Office: Center for Health Systems Research and Analysis
University of Wisconsin Madison
1185 WARF Office Building
610 Walnut Street
Madison, WI 53705
FAX (608) 263-4523 E-mail Ted@chsra.wisc.edu

Experience

- 1984- **Center for Health Systems Research and Analysis**
University of Wisconsin, Madison, Wisconsin
- 1999- *Consultant, Wisconsin Medicaid Program*
Assisted with implementation of point of sale system; evaluated pharmaceutical care payment program, directed redesign of payment system; developed audit program; developed a nursing home reporting system.
- 1990-1997 *Consultant, Nursing Home Case-Mix and Quality Demonstration*
HCFA funded contract to develop quality assurance system based upon drug use information and resident assessment data for nursing home residents. Project involves development and validation of quality indicators, development of reporting system for nursing home surveyors and training surveyors in application of information.
- 1995-1996 *Researcher, Case Study of Pharmacy Benefit Managers*
HCFA funded contract to study the impact of pharmacy benefit managers (PBMs) on costs and quality of care relative to existing Medicaid pharmacy programs.
- 1984-1994 *Director, Wisconsin Medicaid Drug Utilization Review Program (DUR)*
Program development included: creating explicitly defined criteria that limit false positives and emphasize longitudinal analysis; creating software for screening recipient drug use that maximized the use of computer decision support and minimized manual review; implementing interventions to communicate with providers through letters, profiles of practice patterns and face-to-face visits; rigorously evaluating interventions; and establishing statewide drug utilization review committee of clinical and research experts. Supervisor of pharmacy utilization review activities.

- 1993-1994 *Project Manager, Development of DUR Evaluation Methodology.*
 HCFA funded project to develop methodology to be used by State Medicaid programs in evaluating the cost savings as the result of their DUR intervention. The prototype methodology includes research designs that can be used to operationally define the changes in drug and other health care services, changes in direct and indirect expenditures and cost/benefit ratios.
- 1988-1992 *Project Manager, Feasibility of Using Medicaid Data to Target Quality of Care Problems in Long-Term Facilities*
 HCFA funded contract to study the feasibility of using Medicaid claims data to target quality of care problems in long term care facilities, increase the efficiency of survey staff and special consultants. Project includes the development of quality indicators based upon drug use data and diagnostic information from hospital claims, development of a reporting system and evaluation of the demonstration.
- 1997- 1998 **United Government Services**
 Independent pharmacist consultant to Wisconsin Medicaid program. Directing revision to Pharmaceutical Care Payment system. Assisting in the implementation of point-of-sale payment and performing provider audits.
- 1995-1996 **College of Pharmacy (20%)**
 University of New Mexico, Albuquerque, New Mexico
Research Scientist, New Mexico Medicaid Retrospective DUR Project
 Development of retrospective DUR program for New Mexico Medicaid.
- 1986-1994 **Pharmacist Consultant to HMOs**
 Developed drug utilization review programs and assisting in the development of a drug formulary for several HMOs in Wisconsin.
- 1979-1984 **Department of Health and Social Services, State of Wisconsin**
 Madison, Wisconsin
Pharmacy Practices Consultant, Wisconsin Medicaid Program
 Responsible for administering a program that paid for 6,000,000 prescriptions per year of drugs and disposable medical supplies. Monitored claims processing system of Medicaid's fiscal intermediary; provided consultation to auditors, investigators, attorneys and administrators. Served as Department's representative to the Wisconsin Controlled Substances Board. Staffed Wisconsin Drug Quality Council which evaluated generic drugs for inclusion in Wisconsin Drug

Formulary. Participated in state purchasing's annual pharmaceutical bid selection process.

- 1978-1979 **Central Wisconsin Center for Developmentally Disabled**
Madison, Wisconsin
Staff Pharmacist
- 1974-1978 **University of Wisconsin Hospitals and UW School of Pharmacy**
Madison, Wisconsin
Staff Clinical Pharmacist and Clinical Pharmacy Instructor
- 1969-1974 **St. Joseph Hospital**
Marshfield, Wisconsin
Pharmacy Supervisor
- 1967-1969 **Walgreens**
Milwaukee, Wisconsin
Pharmacist Assistant Manager and Intern

Education

B.S., Pharmacy, University of Wisconsin -Madison, June 1967

Professional Organizations

United States Pharmacopeial Convention, Drug Utilization Review Advisory Panel, 1995-2000

American Drug Utilization Review Symposium, Chair of Steering Committee, 1994

American Society of Consultant Pharmacists, Educational Affairs Council, 1994,1995

Wisconsin Cancer Pain Initiative, Chair of Legislative Affairs Committee and Long-term Care Committee, 1993 to1998

Agriculture, Trade and Consumer Protection, Member of Advisory Council, 1983-1995

Wisconsin Pharmacists Association and Long-term Care Section

American Pharmaceutical Association

National Council of Prescription Drug Programs

Publications

Sleath, B, Konrad, TR, Fulda, T, Collins, TM, Medicaid Drug Utilization Review and Managed Care: The Perspectives and Experiences of State Medicaid Directors, *J Managed Care Pharm*, 6:131-36, 2000.

Lipton HL, Kreling, DH, Collins T, Hertz, KC, Pharmacy Benefit Management Companies: Dimensions of Performance, *Ann Rev Public Health*, 20:361-401, 1999.

Mott DA, Collins TM, Comparison of Targeting a Drug Utilization Review Letter Intervention at Pharmacists Separate From and In Addition to Physicians, *Journal of the American Pharmaceutical Association*, 38(3), May 1998

Sleath B, Collins T, Kelly HW, McCament-Mann L, Lien T, Effect of including both physicians and pharmacists in an asthma drug-use review intervention., *Am J Health Syst Pharm*, 54(19), 2197-2200, 01 Oct 1997

Collins TM, Mott DA, Bigelow WE, Zimmerman DR, A controlled letter intervention to change prescribing behavior: results of a dual-targeted approach., *Health Serv Res*, 32(4), 471-489, Oct 1997

Sleath B, Collins T, Physician Responses to an Educational Intervention on Improving their Long-term Prescribing of Sedatives, *Patient Education and Counseling*, 31(3), 215-222, Jul 1997

Sleath B, McCament-Mann, L, Collins T, Hollarbush J, Response Forms Reflect Pharmacists' Participation in Retrospective DUR. *Journal of the American Pharmaceutical Association*, NS37(1), 77-84, Jan 1997

Kreling DH, Lipton HL, Collins T, Hertz KC. Assessment of the Impact of Pharmacy Benefit Managers, HCFA Master Contract 95-023/PK, September 30, 1996.

Zimmerman, DR, Karon SL, Arling G, Clark BR, Collins T, Ross, R, Sanifort F. Development and Testing of Nursing Home Quality Indicators. *Health Care Financing Review* 16:4; 107-127 (Summer), 1995.

Lipowski EE, Collins TM. Medicaid DUR Programs, 1993: Final Report to American Pharmaceutical Association Foundation, September, 1995.

Zimmerman D, Collins T, Lipowski EE, Kreling D, Wiederholt, J. Guidelines for Estimating the Impact of Medicaid DUR. HCFA Contract #500-93-0032. August, 1994

Zimmerman DR, Collins TM, Lipowski EE, Sanifort F. Evaluation of DUR Intervention: A Case Study of Histamine Antagonists. *Inquiry*. 31:89-101 (Spring), 1994.

Collins TM, Zimmerman DR. Programs for Monitoring the Inappropriate Prescribing of Controlled Drugs: Evaluation and Recommendations. *American Journal of Hospital Pharmacy* 49:1765-1768, 1992.

Collins TM. Multiple copy Prescription Programs and Alternative Monitoring Programs: Cost Issues. *New York State Journal of Medicine* 91:28S-31S, 1991.

Arling G, Ryther BJ, Collins T, Zimmerman D. Mental Illness and Psychotropic Medication Use in the Nursing Home. *Journal of Aging and Health* 3:455-472, 1991.

Lipowski, EE, Bauwens, SF, Collins TM. An Examination of Histamine-2 Antagonist Utilization by Medicaid Recipients in Wisconsin Long Term Care Facilities. *Journal of American Geriatrics Society* 36:531-536, 1988.

Lipowski, EE, Wiederholt JB, Kreling DH, Collins TM. Use of a Medicaid Database to Analyze Pharmaceutical Services in Long Term Care Facilities. *American Journal of Hospital Pharmacy* 43:1467-1472, 1986.

Presentations

Changes in Long Term Care policy and the impact on DUR, American Drug Utilization Review Symposium, Dallas, TX, February, 1999

Wisconsin Medicaid Pharmaceutical Care Initiative, National Medicaid Pharmacist Consultant Conference, Asheville, NC, March, 1997.

Measuring Quality in Medicaid Managed Care, American Drug Utilization Review Symposium, February, 1997.

Quality Indicators in Long-term Care, American Society of Consultant Pharmacists Midyear Conference, Marco Island, Florida, May, 1996

Drug Utilization Review World Wide Web Site, American Drug Utilization Review Symposium, February, 1996

Pharmacy Benefit Managers and Drug Utilization Review, Representatives of Japanese pharmaceutical companies, Tokyo, Japan, November, 1995

Impact of Federal and State Controls on Prescribing and Dispensing of Opioids, Georgia Osteopathic Association, June, 1995

DUR: Provider profiling, American Society of Health Systems Pharmacists, June, 1995

Impact of Federal and State Controls and Prescribing and Dispensing of Opioids, Alabama Podiatric Association, June, 1995

DUR Interventions, National Invitational Conference on DUR for Pharmacy Faculty, March, 1995

Provider Profiling, Conference on Pharmacy Networks, March, 1995

Provider Profiling, American Drug Utilization Review Symposium, February, 1995

Demystifying DUR, A Process Approach, American Pharmaceutical Association, March, 1994